Press release
Analysis of Segments and Major Growth Areas in the Tuberculosis Therapeutics Market
Tuberculosis Therapeutics Market
Tuberculosis Therapeutics Market Size and Growth Potential
The market for tuberculosis therapeutics is projected to expand steadily, reaching a valuation of $2.7 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 6.1% during the forecast period. Factors contributing to this upward trend include the rising incidence of multidrug-resistant tuberculosis (TB), progress in the development of novel TB drugs, increased global funding for health programs, wider adoption of digital adherence technologies, and an intensified focus on preventive TB treatments. Key trends shaping the market encompass the development of therapies targeting drug-resistant TB, broader use of combination treatment regimens, emphasis on shorter treatment durations, expansion of public health initiatives, and improved strategies for monitoring patient adherence.
Download a free report of the tuberculosis therapeutics market report:
https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Top Companies Leading the Tuberculosis Therapeutics Market
Several prominent organizations are at the forefront of the tuberculosis therapeutics market. These include Pfizer Inc, Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Sanofi S.A, Novartis AG, GlaxoSmithKline plc, Viatris Inc, Cipla Limited, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Sequella Inc, AstraZeneca plc, Eli Lilly and Company, Biofabri S L, LegoChem Biosciences, BioVersys AG, SENTAN Pharma Inc, ViChem Pharmaceuticals Inc, PDS Biotechnology Corporation, BioNTech SE, and Qurient Co Ltd.
A notable collaboration occurred in May 2024 when Swiss biotech firm BioVersys AG partnered with UK-based GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for tuberculosis treatment. GSK plc specializes in innovative medicines, including TB therapeutics, and this partnership aims to fast-track promising drug candidates to address the disease more effectively.
Emerging Trends Transforming Tuberculosis Therapeutics
Leading companies in the tuberculosis therapeutics space are increasingly focusing on innovative approaches like combination therapy to enhance treatment outcomes. Combination therapy involves using multiple medications from different drug classes to boost efficacy, reduce resistance, and improve patient adherence.
For example, in July 2024, Johnson & Johnson achieved a landmark advancement with regulatory approvals from the U.S. FDA and the European Commission for SIRTURO (bedaquiline). This drug is the first in over forty years specifically designed to target multidrug-resistant tuberculosis (MDR-TB). SIRTURO works by inhibiting ATP synthase, an enzyme crucial for the energy production of TB bacteria, offering a focused and effective treatment. When used in combination regimens, it helps shorten treatment duration and enhances patient compliance.
View the full tuberculosis therapeutics market report:
https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Market Segmentation Overview of Tuberculosis Therapeutics
The tuberculosis therapeutics market is segmented into several categories to provide a detailed understanding of its scope:
1) By Type: Active Tuberculosis (TB) and Latent Tuberculosis (TB)
2) By Drug Type: Isoniazid, Rifampin, Pyrazinamide, Hydrazine derivatives, Miscellaneous anti-tubercular drugs, and Ethambutol
3) By Route of Administration: Oral, Parenteral, and Other routes
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, and other end-users
Further subdivisions within the active TB segment include first-line drugs such as Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol; second-line drugs like Fluoroquinolones and Aminoglycosides; combination therapies; and drug-resistant TB treatments addressing MDR-TB and XDR-TB. For latent TB, subcategories cover Isoniazid prophylaxis, Rifampicin-based regimens, Rifapentine-based regimens, and combination prophylactic therapies.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Analysis of Segments and Major Growth Areas in the Tuberculosis Therapeutics Market here
News-ID: 4487421 • Views: …
More Releases from The Business Research Company
Competitive Landscape: Key Market Leaders and Rising Competitors in the Contrace …
The contraceptives market is positioned for significant expansion over the coming years, driven by innovation and growing awareness about reproductive health. Advances in technology, evolving consumer preferences, and broader access to contraceptive options are shaping this dynamic industry. Below is a detailed overview of the market size, key players, prevailing trends, and segmentation.
Forecasted Growth and Market Size of the Contraceptives Market by 2030
The contraceptives market is projected to…
Growth Patterns, Market Segmentation, and Competitive Approaches Influencing the …
The constrained peptide drugs market is attracting significant attention due to its promising growth potential and innovative therapeutic applications. As the pharmaceutical industry advances, these specialized peptides are expected to revolutionize treatment options for complex diseases, offering improved efficacy and targeted delivery. Here's a detailed exploration of the market's size, key players, emerging trends, and major segments shaping its future.
Projected Market Value and Growth Rates for Constrained Peptide Drugs …
Segmentation, Major Trends, and Competitive Overview of the Conjugated Monoclona …
The conjugated monoclonal antibodies market is on track for significant expansion over the coming years, driven by advancements in technology and increased adoption in cancer treatment. This segment holds promising potential as it evolves with new innovations and growing investment in oncology research. Let's explore the current market valuation, key players, emerging trends, and the main segments shaping the future of conjugated monoclonal antibodies.
Projected Market Valuation and Growth Path of…
Leading Companies Reinforcing Their Presence in the Compression Therapy Market
The compression therapy industry is poised for remarkable expansion as healthcare continues to evolve with new technologies and growing patient needs. This sector is becoming increasingly vital, especially for managing vascular and circulatory conditions, with innovations driving greater adoption and improved outcomes. Below is a detailed look at the market's size, key players, influential trends, and segmentation.
Compression Therapy Market Size Set for Significant Growth by 2030
The compression therapy…
More Releases for Tuberculosis
Revolutionizing the Fight Against Tuberculosis: Global Anti-Tuberculosis Therape …
The global Anti-Tuberculosis (TB) Therapeutics Market is on the cusp of a transformative era, driven by urgent medical need, groundbreaking scientific advances, and expanding public-private partnerships. With an estimated 10 million new TB cases reported worldwide in 2022 and 1.4 million deaths, tuberculosis remains a leading infectious disease killer, commanding critical attention from healthcare providers, governments, and pharmaceutical innovators alike. As the world rallies to eliminate this centuries-old scourge, the…
Latent Tuberculosis Infection Detection Market
Latent Tuberculosis Infection Detection Market worth $2.37 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Latent Tuberculosis Infection Detection Market - (By Brand (QFT-Plus), By Test Type (Tuberculin Skin Test (TST), Interferon Gamma Release Assay (IGRA)), By Application, By End-use), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research…
Tuberculosis (TB) Diagnostics Market - Detect, Diagnose, Defeat: Innovating Solu …
Newark, New Castle, USA - new report, titled Tuberculosis (TB) Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Tuberculosis (TB) Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Tuberculosis (TB) Diagnostics market. The report offers an overview of…
Conquering Tuberculosis: Exploring the Innovations in Mycobacterium Tuberculosis …
The global mycobacterium tuberculosis treatment market was valued at US$ 1.97 Bn in 2021 and is expected to increase at a CAGR of 1.2% over the forecast period 2022-2032.
Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB), which mostly affects the lungs. Tuberculosis is a major public health crisis concern; however, it can be cured and prevented. Adults are most often affected by tuberculosis during their most productive years. Over…
World Tuberculosis Day - Tuberculosis, the invisible pandemic
Tuberculosis is a disease that, every year, kills as many as COVID-19 does.
March 24, World Tuberculosis Day, marks the anniversary of a momentous occasion - the discovery of the bacterium which causes tuberculosis in 1882. More than a hundred years after its discovery, tuberculosis is still a global health crisis. It is the leading cause of death from a single infectious disease agent, killing close to as many people per…
Ocular Tuberculosis Therapeutics Market To Expand On Account Of Rising Tuberculo …
Research Nester released a report titled “Ocular Tuberculosis Therapeutics Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global ocular tuberculosis therapeutics market in terms of market segmentation by treatment, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
Ocular tuberculosis is a type…
